Viewing data from:

AMIKACIN SULFATE

ANDA

AMIKACIN SULFATE | A063167 | IGI LABORATORIES INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Amikacin Sulfate (2023)

Total Spending

$1.2M

Total Claims

12,098

Beneficiaries

2,801

Avg Cost/Unit

$1.87

Spending Trend

$1.5M(2019)→$1.3M(2020)→$1.2M(2021)→$1.1M(2022)→$1.2M(2023)

YoY Change:-5.9%

5yr CAGR:-7.7%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain2 active DMFs7 inactive

2 active API suppliers hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

ACS DOBFAR SPAAMIKACIN SULFATE

DMF 137631998

SHANDONG ANXIN PHARMACEUTICAL CO LTDAMIKACIN SULFATE USP, NON-STERILE ACTIVE PHARMACEUTICAL INGREDIENT

DMF 208742007

CHEMICAL PHARMACEUTICAL RESEARCH INSTITUTE NIHFI LTDInactiveAMIKACIN SULFATE

DMF 106801993

GIST-BROCADES NV PHARMACEUTICALSInactiveAMIKACIN SULFATE

DMF 136511998

BRISTOL MYERS SQUIBB COInactiveAMIKACIN SULFATE

DMF 137221998

ABBOTT LABORATORIESInactiveAMIKACIN SULFATE

DMF 137561998

CHONGQING DAXIN PHARMACEUTICAL CO LTDInactiveAMIKACIN SULFATE (1:2) USP

DMF 137881998

PKUCARE CHONGQING DAXIN PHARMACEUTICAL CO LTDInactiveAmikacin Sulfate (1:1.8) USP, Non-Sterile Bulk Drug Substance

DMF 210352007

ZHEJIANG JINHUA CONBA BIO-PHARM CO LTDInactiveAMIKACIN SULFATE USP

DMF 277762013

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — EQ 50MG BASE/ML

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Dec 14, 1995

No patent or exclusivity listings for this strength.